K
KODIAK SCIENCES INC
NASDAQ: KOD (Kodiak Sciences Inc)
Last update: 2 hours ago81.09
-10.54 (-11.50%)
| Previous Close | 91.63 |
| Open | 90.48 |
| Volume | 2,405,677 |
| Avg. Volume (3M) | 1,607,340 |
| Market Cap | 5,096,462,336 |
| Price / Book | 34.79 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Diluted EPS (TTM) | -3.62 |
| Total Debt/Equity (MRQ) | 62.14% |
| Current Ratio (MRQ) | 4.62 |
| Operating Cash Flow (TTM) | -106.80 M |
| Levered Free Cash Flow (TTM) | -34.64 M |
| Return on Assets (TTM) | -34.10% |
| Return on Equity (TTM) | -108.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Kodiak Sciences Inc | Mixed | Bullish |
AIStockmoo Score
-1.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.17 |
Select this tab to load the latest available analysis.
|
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.52% |
| % Held by Institutions | 81.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Iconiq Capital, Llc | 30 Jun 2026 | 1,266,563 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |